AposHealth

Company Overview

Snapshot

Founded in January 2004, AposHealth operates with 51–200 employees. The company has raised $37 million across 5 funding rounds from 5 investors. In February 2020, AposHealth announced an $11 million Series A extension funding round.

Business overview

AposHealth develops solutions for identifying and treating gait-related conditions within the Health Tech & Life Sciences sector. Its core product, the Apos3 device, is FDA-cleared for knee osteoarthritis treatment, aiming to reduce pain and improve lower extremity function. Additionally, it serves as a non-FDA-cleared wellness device for other gait-related issues like chronic low back and hip pain. Through its AposIQ business unit, the company leverages innovative technology and data science to optimize gait adjustments, serving markets in the United Kingdom, United States, and Singapore.

Strategic signal

In May 2020, research published in The Journal of the American Medical Association (JAMA) highlighted that knee osteoarthritis patients treated with AposTherapy experienced significant pain reduction. This publication provides strong clinical validation for AposHealth's technology, reinforcing its efficacy and potentially expanding its adoption among healthcare providers and patients seeking non-surgical solutions for chronic pain.

Company Intelligence Q&A

What was the most recent funding event for AposHealth?

In February 2020, AposHealth announced an $11 million Series A extension funding round, led by existing shareholders including aMoon Fund.

Which investors participated in the November 2014 funding round?

In November 2014, AposHealth received funding from Aviv Venture Capital and Invus.

What was the focus of AposTherapy's partnerships in March 2020?

In March 2020, AposTherapy partnered with three physical therapy providers in Queens, New York, to offer its non-surgical, drug-free solution for knee and lower back pain sufferers. The company also expanded its partnership with Professional Physical Therapy to additional Massachusetts locations.

What significant research was published regarding AposTherapy in May 2020?

In May 2020, research published in The Journal of the American Medical Association (JAMA) showed that knee osteoarthritis patients treated with AposTherapy experienced significant pain reduction.

When did Healthfirst New York formalize coverage for AposTherapy?

In August 2020, Healthfirst New York formalized coverage of AposTherapy, an innovative therapy designed for use in orthopedic conditions.